Acorda Therapeutics, Inc.
ACORDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001008848
Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Acorda Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −1 vs. Q3 2023
- Shares held
- 157.6K
- −1.90K (−1.2%) vs. Q3 2023
- Total value
- $2.33M
- +$30.5K (+1.3%) vs. Q3 2023
- New holders
- 1
- 4 more added
- Sold out
- 2
- 3 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 2 | $8.00K |
| Q1 2024 | 17 | $2.13M |
| Q4 2023 | 15 | $2.33M |
| Q3 2023 | 16 | $2.30M |
| Q2 2023 | 15 | $1.94M |
| Q1 2023 | 30 | $3.71M |
| Q4 2022 | 36 | $4.09M |
| Q3 2022 | 36 | $1.91M |
| Q2 2022 | 35 | $3.08M |
| Q1 2022 | 34 | $5.42M |
| Q4 2021 | 34 | $9.48M |
| Q3 2021 | 36 | $14.7M |
| Q2 2021 | 37 | $18.1M |
| Q1 2021 | 37 | $18.0M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Acorda Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Davidson Kempner Capital Management LP | 55,145 | $801.3K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 45,761 | $691.0K | 0.00% | −300−0.7% | Reduced |
| Acadian Asset Management LLC | 33,691 | $489.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 10,808 | $163.1K | 0.00% | +74+0.7% | Added |
| BlackRock Inc. | 6,628 | $100.0K | 0.00% | −150−2.2% | Reduced |
| Wells Fargo & Company | 3,741 | $56.5K | 0.00% | +10.0% | Added |
| Morgan Stanley | 1,176 | $17.7K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 298 | $4.50K | 0.00% | +164+122.4% | Added |
| Russell Investments Group, Ltd. | 300 | $4.36K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 50 | $754 | 0.00% | +50 | New |
| First Manhattan Co | 3 | $45 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 3 | $44 | 0.00% | +1+50.0% | Added |
| Advisor Group Holdings, Inc. | 1 | $15 | 0.00% | −1−50.0% | Reduced |
| Qube Research & Technologies Ltd | 1 | $15 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 14 | $0 | 0.00% | 00.0% | Unchanged |
| Deutsche Bank AG | 0 | $0 | 0.00% | −1,700−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −41−100.0% | Sold out |